A carregar...
Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
Effectiveness, efficacy and safety of biosimilar infliximab (CT-P13) in inflammatory bowel disease (IBD) patients has been shown in previous studies. Limited data exist on health-related quality of life (HRQoL) of switching originator to biosimilar infliximab (IFX) in IBD patients. The objective of...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6959900/ https://ncbi.nlm.nih.gov/pubmed/31914087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000018723 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|